BRAF V600E mutations are downstream targets of the RAS signaling pathway and are altered in 10% of colorectal cancer (CRC) patients; these mutations are also mutually exclusive with the KRAS mutation [8]. The gene discussed is KRAS; the disease is colorectal carcinoma.